Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.55 |
| ▸ | CCNC | P24863 | 10/20 | 0.50 |
| ▸ | CDK8 | P49336 | 10/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | MYLK | Q15746 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CILK1 | Q9UPZ9 | 1/20 | 0.42 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.42 |
| ▸ | WNT1 | P04628 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18318325 | 0.86 | CYP11B2 (0.55) | CYP11B2CYP11B1CCNCCDK8ROCK2 | |
| Hydrochloric Acid SCHEMBL18318577 | 0.85 | CYP11B2 (0.54) | CYP11B2CYP11B1CCNCCDK8ROCK2 | |
| SCHEMBL31673855 | 0.78 | PIK3CA (0.51) | — | |
| SCHEMBL18318741 | 0.78 | PIK3CA (0.51) | — | |
| SCHEMBL4440476 | 0.77 | BLM (0.53) | — | |
| SCHEMBL18318091 | 0.76 | FASN (0.47) | NAMPT | |
| SCHEMBL31696890 | 0.76 | CYP11B1 (0.55) | CYP11B2CYP11B1CCNCCDK8ROCK2 | |
| SCHEMBL18321547 | 0.76 | CYP11B1 (0.55) | CYP11B2CYP11B1CCNCCDK8ROCK2 | |
| SCHEMBL31696908 | 0.75 | CYP11B2 (0.54) | CYP11B2CYP11B1CCNCCDK8ROCK2 | |
| SCHEMBL18321643 | 0.75 | CYP11B2 (0.54) | CYP11B2CYP11B1CCNCCDK8ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | claimed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | claimed |
| CN-107847765-B | 1, 4-substituted piperidine derivatives | 89生物有限公司 | 2021-05-04 | — | — | CN | claimed |
| EP-3310441-B1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-07-29 | — | — | EP | claimed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | claimed |
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2025-08-14 | — | — | US | disclosed |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2024-09-24 | — | — | US | disclosed |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2023-12-07 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | 89BIO LTD (IL) | 2023-07-18 | — | — | US | disclosed |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | CEPHALON LLC | 2021-07-29 | — | — | US | disclosed |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2018-06-28 | — | — | US | disclosed |
| EP-3310441-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902696-B2 | 1,4-substituted piperidine derivatives | CEPHALON, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON LLC | 2016-12-22 | — | — | US | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016205633-A1 | 1, 4-SUBSTITUTED PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257035-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | CYP11B2 496/4885CYP11B1 264/4885CCNC 3975/4885 |
| US-20230391723-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | CYP11B2 496/4885CYP11B1 264/4885CCNC 3975/4885 |
| US-20160368874-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | CYP11B2 496/4885CYP11B1 264/4885CCNC 3975/4885 |
| US-20210230116-A1 | 1,4-Substituted Piperidine Derivatives | FASN, CES1, CPT1A | CYP11B2 496/4885CYP11B1 264/4885CCNC 3975/4885 |
| US-11702388-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | CYP11B2 496/4885CYP11B1 264/4885CCNC 3975/4885 |
| US-12098130-B2 | 1,4-substituted piperidine derivatives | FASN, CES1, CPT1A | CYP11B2 496/4885CYP11B1 264/4885CCNC 3975/4885 |
| US-20180179159-A1 | 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES | FASN, CES1, CPT1A | CYP11B2 457/4885CYP11B1 254/4885CCNC 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.